The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Open accessAbstract
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, BRAF inhibitors led to a monotherapy response rate of >50% in BRAFV600E melanoma and ~30% in BRAFV600E NSCLC, but only ~5% in BRAFV600E colorectal cancer, likely due to the variable robustness of adaptive feedback networks in each tumor type (45–49).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Cited by
Sorted by citations
Items 701–800 of 1,003
Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH
Ruzzolini, J., Peppicelli, S., Andreucci, E., Bianchini, F., Margheri, F., Laurenzana, A., Fibbi, G., Pimpinelli, N., & Calorini, L. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.010 · Cited by 41
Liu, X., Feng, Y., Xu, G., Yang, C., Luo, Y., Song, J., Bao, Y., Yang, J., Yu, C., Li, Y., et al. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201806916 · Cited by 39
de Andrés, J. L., Ruiz-Toranzo, M., Antich, C., Chocarro‐Wrona, C., López‐Ruiz, E., Jiménez, G., & Marchal, J. A. (2022) · Biofabrication · doi:10.1088/1758-5090/ac8dc6 · Cited by 41
Qiao, S., Cabello, C. M., Lamore, S. D., Lesson, J. L., & Wondrak, G. T. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0746-x · Cited by 39
Diffuse melanosis cutis: A systematic review of the literature
Sebaratnam, D. F., Venugopal, S. S., Frew, J. W., McMillan, J. R., Finkelstein, E., Martin, L. K., & Murrell, D. F. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.08.018 · Cited by 39
Hurabielle, C., Pillebout, É., Stehlé, T., Pagès, C., Roux, J., Schneider, P., Chevret, S., Chaffaut, C., Boutten, A., Mourah, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149873 · Cited by 39
Cohen, P. R., Bedikian, A. Y., & Kim, K. B. (2013) · PubMed Central · Cited by 38
Self-citationSide effects of systemic oncological therapies in dermatology
Zimmer, L., Vaübel, J., Livingstone, E., & Schadendorf, D. (2012) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07942.x · Cited by 38
The MAPK pathway as an apoptosis enhancer in melanoma
Haydn, J. M., Hufnagel, A., Grimm, J., Maurus, K., Schartl, M., & Meierjohann, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2079 · Cited by 39
Reed, D. R., Kudchadkar, R. R., Zager, J. S., Sondak, V. K., & Messina, J. L. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0087 · Cited by 38
Tromme, I., Devleesschauwer, B., Beutels, P., Richez, P., Leroy, A., Baurain, J. F., Cornelis, F., Bertrand, C., Legrand, N., Degueldre, J., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13262 · Cited by 38
Dudley, J. C., Gurda, G. T., Tseng, L., Anderson, D. A., Chen, G., Taube, J. M., Gocke, C. D., Eshleman, J. R., & Lin, M. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0091-6 · Cited by 38
Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management
Liu, S., & Kurzrock, R. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.032 · Cited by 38
Patel, B. G., Ahmed, K. A., Johnstone, P. A. S., Yu, H.-H. M., & Etame, A. B. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000250 · Cited by 38
Chisholm, J., Suvada, J., Dunkel, I. J., Casanova, M., Zhang, W., Ritchie, N., Choi, Y., Park, J., Thakur, M. D., Simko, S. J., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.26947 · Cited by 39
Mastorakos, P., Xu, Z., Yu, J. B., Hess, J. A., Qian, J. M., Chatrath, A., Taylor, D. G., Kondziolka, D. S., Warnick, R. E., Chiang, V., et al. (2018) · Neurosurgery · doi:10.1093/neuros/nyy203 · Cited by 38
Tarlock, K., Zhong, S., He, Y., Ries, R. E., Severson, E. A., Bailey, M., Morley, S., Balasubramanian, S., Erlich, R., Lipson, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25443 · Cited by 41
Yan, Y., Wongchenko, M. J., Robert, C., Larkin, J., Ascierto, P. A., Dréno, B., Maio, M., Garbe, C., Chapman, P. B., Sosman, J. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0720 · Cited by 38
Self-citationIdentifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer
Cronise, K. E., Hernandez, B. G., Gustafson, D. L., & Duval, D. L. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115808 · Cited by 38
Ali, E. M. H., Abdel‐Maksoud, M. S., Ammar, U. M., Mersal, K. I., Yoo, K. H., Jooryeong, P., & Oh, C. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104508 · Cited by 38
Regorafenib for Gastrointestinal Malignancies
Aprile, G., Macerelli, M., & Giuliani, F. (2013) · BioDrugs · doi:10.1007/s40259-013-0014-9 · Cited by 38
Specifying protein kinase C functions in melanoma
Denning, M. F. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.01015.x · Cited by 40
Cheng, H., Chang, Y., Zhang, L., Luo, J., Tu, Z., Lu, X., Zhang, Q., Lu, J., Ren, X., & Ding, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500007h · Cited by 39
Progression of cutaneous melanoma: implications for treatment
Leong, S. P. L., Mihm, M. C., Murphy, G. F., Hoon, D. S. �., Kashani–Sabet, M., Agarwala, S. S., Zager, J. S., Hauschild, A., Sondak, V. K., Guild, V., et al. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9521-1 · Cited by 38
BRAF-induced tumorigenesis is IKKα-dependent but NF-κB–independent
Margalef, P., Colomer, C., Villanueva, A., Montagut, C. O., Iglesias, M., Bellosillo, B., Salazar, R., Martínez‐Iniesta, M., Bigas, A., & Espinosa, L. (2015) · Science Signaling · doi:10.1126/scisignal.2005886 · Cited by 38
Barbano, R., Pasculli, B., Coco, M., Fontana, A., Copetti, M., Rendina, M., Valori, V. M., Graziano, P., Maiello, E., Fazio, V. M., et al. (2015) · Scientific Reports · doi:10.1038/srep18592 · Cited by 38
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
GENOME-WIDE ANALYSIS OF TRIPLE-NEGATIVE PHENOTYPE BREAST TUMORS
Ibragimova, М. K., Tsyganov, M. M., & Litvyakov, N. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.31 · Cited by 37
ACCOMPANYING TRANSCRANIAL MAGNETOTHERAPY IN COMBINATION TREATMENT OF HIGH-GRADE GLIAL BRAIN TUMORS
Popov, I. A., Shikhlyarova, A. I., Frantsiyants, E. M., & Kaplieva, I. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.30 · Cited by 37
Mollaev, M. D., Вихрева, П. Н., Кибардин, А. В., Mayorova, V. E., Kholodenko, R. V., Kulakovskaya, E. A., Pershin, D., Maschan, M. A., & Larin, S. S. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.12 · Cited by 37
STUDY OF BIOLOGICAL ACTIVITY OF DOXORUBICIN CONJUGATE WITH NACETYL-D-GALACTOSAMINE HYDRASONIC LINKER
Pestretsova, A. S., Kozina, D. V., Sokolova, D. V., Pokrovsky, V. S., & Beloglazkina, E. K. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.18 · Cited by 37
INFLUENCE OF HYPOTHYROIDISM ON THE HYPOTHALAMIC-PITUITARYGONADAL AXIS IN RATS WITH GUERIN'S TUMOR
Frantsiyants, E. M., Bandovkina, V. A., Kaplieva, I. V., Surikova, E. I., Neskubina, I. V., Trepitaki, L. K., Shikhlyarova, A. I., Goroshinskaya, I. A., Zhukova, G. V., Nemashkalova, L. A., et al. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.26 · Cited by 37
The sweet and bitter sides of galectins in melanoma progression
Braeuer, R. R., Shoshan, E., Kamiya, T., & Bar‐Eli, M. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.01026.x · Cited by 38
Pharmacogenetic Markers of Drug Efficacy and Toxicity
Yip, V., Hawcutt, D. B., & Pirmohamed, M. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.135 · Cited by 38
RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells
Berger, A., Quast, S.-A., Plötz, M., Kuhn, N. F., Trefzer, U., & Eberle, J. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.347 · Cited by 37
C-RAF Mutations Confer Resistance to RAF Inhibitors
Antony, R., Emery, C. M., Sawyer, A. M., & Garraway, L. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4089 · Cited by 39
Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Metastatic Melanoma
Klein, O., Ribas, A., Chmielowski, B., Walker, G. L., Clements, A., Long, G. V., & Kefford, R. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.7028 · Cited by 37
Self-citationUnderstanding the Biology of Melanoma and Therapeutic Implications
Sullivan, R. J., & Fisher, D. E. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.007 · Cited by 40
S̄pitler, L. E., Boasberg, P. D., Day, S. O., Hamid, O., Cruickshank, S., Mesko, S. M., & Weber, R. W. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318287bbae · Cited by 38
Regulating the response to targeted MEK inhibition in melanoma
Conrad, W. H., Swift, R. D., Biechele, T. L., Kulikauskas, R. M., Moon, R. T., & Chien, A. J. (2012) · Cell Cycle · doi:10.4161/cc.21645 · Cited by 37
Richter, A. M., Grieu, F., Carrello, A., Amanuel, B., Namdarian, K., Rynska, A., Lucas, A., Michael, V., Bell, A. H., Fox, S. B., et al. (2013) · Scientific Reports · doi:10.1038/srep01659 · Cited by 37
Self-citationEconomic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
Bilir, S. P., Ma, Q., Zhao, Z., Wehler, E., Munakata, J., & Barber, B. (2016) · Europe PMC (PubMed Central) · Cited by 37
Theodosakis, N., Micevic, G., Langdon, C. G., Ventura, A., Means, R. E., Stern, D. F., & Bosenberg, M. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.12.033 · Cited by 38
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 39
Li, H., Liu, J., Xiao, X., Sun, S., Zhang, Y., Zhang, Y., Zhou, W., Zhang, B., Roy, M., Liu, H., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.005 · Cited by 37
Krummel, D. P., Nasti, T. H., Kaluzová, M., Kallay, L. M., Bhattacharya, D., Melms, J. C., Izar, B., Xu, M., Burnham, A. J., Ahmed, T., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.10.025 · Cited by 38
NECTIN4: A Novel Therapeutic Target for Melanoma
Tanaka, Y., Murata, M., Shen, C., Furue, M., & Ito, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020976 · Cited by 37
Wenk, K. S., Pichard, D. C., Nasabzadeh, T. J., Jang, S., & Venna, S. S. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.5278 · Cited by 37
Long, J. E., Wongchenko, M. J., Nickles, D., Chung, W., Wang, B.-E., Riegler, J., Li, J., Li, Q., Sandoval, W. N., Eastham-Anderson, J., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0310-0 · Cited by 37
Self-citationGrazia, G., Penna, I., Perotti, V., Anichini, A., & Tassi, E. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2491 · Cited by 38
Anaplastic thyroid cancer: Rare, fatal, and neglected
Kebebew, E. (2012) · Surgery · doi:10.1016/j.surg.2012.08.059 · Cited by 36
Vemurafenibfor the treatment of melanoma
Jordan, E., & Kelly, C. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.737780 · Cited by 36
Targeted Therapies Combined With Immune Checkpoint Therapy
Prieto, P. A., Reuben, A., Cooper, Z. A., & Wargo, J. A. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000182 · Cited by 37
Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
Argenziano, G., Banzi, C., Blasio, S. D., Lallas, A., Longo, C., Moscarella, E., & Alfano, R. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s75104 · Cited by 37
Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma
Zhao, Y., Zhang, B., Yu, L., Sun, J., Zhang, Y., Yang, S., & Zhang, X. (2016) · Tumor Biology · doi:10.1007/s13277-016-5212-x · Cited by 36
BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities
Rizzo, D., Ruggiero, A., Amato, M., Maurizi, P., & Riccardi, R. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1214710 · Cited by 36
Integrating Models to Quantify Environment-Mediated Drug Resistance
Picco, N., Sahai, E. A., Maini, P. K., & Anderson, A. R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0835 · Cited by 38
MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity in Melanoma
Sahoo, A., Sahoo, S. K., Joshi, P. K., Lee, B., & Perera, R. J. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.06.189 · Cited by 38
Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma
Rubio‐Rivas, M., Moreira, C., & Marcoval, J. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102587 · Cited by 36
Current and emerging treatment options for metastatic melanoma: a focused review
Nguyen, K., Hignett, E., & Khachemoune, A. (2020) · Dermatology Online Journal · doi:10.5070/d3267049551 · Cited by 38
Non-coding RNAs in melanoma: Biological functions and potential clinical applications
Qiu, P., & Wang, J. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.012 · Cited by 38
Nguyen, L. C., Naulaerts, S., Bomane, A., Bruna, A., Ghislat, G., & Ballester, P. J. (2021) · Biomedicines · doi:10.3390/biomedicines9101319 · Cited by 36
Ma, C., Fan, R., & Elitaş, M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00133 · Cited by 36
Human cancer regression antigens
Kvistborg, P., van Buuren, M. M., & Schumacher, T. N. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.005 · Cited by 36
Longacre, T. A., Broaddus, R. R., Chuang, L. T., Cohen, M. B., Jarboe, E. A., Mutter, G. L., Otis, C. N., & Zaino, R. J. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0450-cp · Cited by 36
p53 Family in Resistance to Targeted Therapy of Melanoma
Vlašić, I., Horvat, A., Tadijan, A., & Slade, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010065 · Cited by 36
Singhal, R., & Kandel, E. (2012) · Oncotarget · doi:10.18632/oncotarget.587 · Cited by 35
High‐throughput sequencing of the melanoma genome
Kunz, M., Dannemann, M., & Kelso, J. F. (2012) · Experimental Dermatology · doi:10.1111/exd.12054 · Cited by 36
Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
Klinac, D., Gray, E. S., Millward, M. J., & Ziman, M. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00054 · Cited by 38
Makino, E., Gutmann, V., Kosnopfel, C., Niessner, H., Forschner, A., Garbe, C., Sinnberg, T. W., & Schittek, B. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0952-8 · Cited by 35
Basket Designs: Statistical Considerations for Oncology Trials
Kaizer, A. M., Koopmeiners, J. S., Kane, M. J., Roychoudhury, S., Hong, D. S., & Hobbs, B. P. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00194 · Cited by 35
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
Meirson, T., Asher, N., Bomze, D., & Markel, G. (2020) · Cancers · doi:10.3390/cancers12061650 · Cited by 36
Gong, B., Li, D., Kusko, R. L., Novoradovskaya, N., Zhang, Y., Wang, S., Pabón-Peña, C., Zhang, Z., Lai, K., Cai, W., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02315-0 · Cited by 38
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 38
Theodosakis, N., Held, M. A., Marzuka-Alcalá, A., Meeth, K. M., Micevic, G., Long, G. V., Scolyer, R. A., Stern, D. F., & Bosenberg, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0080 · Cited by 36
The FBXO4 Tumor Suppressor Functions as a Barrier to Braf V600E -Dependent Metastatic Melanoma
Lee, E. K., Lian, Z., D'Andrea, K. P., Letrero, R., Sheng, W., Liu, S., Diehl, J. A., Pytel, D., Barbash, O., Schuchter, L. M., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00706-13 · Cited by 37
Self-citationTeuma, C., Perier‐Muzet, M., Pelletier, S., Nouvier, M., Amini‐Adlé, M., Dijoud, F., Duru, G., Thomas, L., Fouque, D. P., Laville, M., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3086-7 · Cited by 35
The Genomic Landscape of Melanoma and Its Therapeutic Implications
Yang, T., Yu, S., Ke, C. K., & Cheng, S. (2023) · Genes · doi:10.3390/genes14051021 · Cited by 36
Kang, S., Kim, J., Song, N. R., Jung, S. K., Lee, M. H., Park, J. S., Yeom, M., Bode, A. M., Dong, Z., & Lee, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104305 · Cited by 34
'Toxgnostics': an unmet need in cancer medicine
Church, D. N., Kerr, R. S., Domingo, E., Rosmarin, D., Palles, C., Maskell, K. F., Tomlinson, I. P. M., & Kerr, D. J. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3729 · Cited by 34
Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas
Regnier-Rosencher, E., Lazareth, H., Gressier, L., Avril, M.-F., Thervet, É., & Dupin, N. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12555 · Cited by 34
The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
Liu, X., Wu, J., Qin, H., & Xu, J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0565-2 · Cited by 36
Hawerkamp, H. C., Kislat, A., Gerber, P. A., Pollet, M., Rolfes, K. M., Soshilov, A. A., Denison, M. S., Momin, A. A., Arold, S. T., Datsi, A., et al. (2019) · Allergy · doi:10.1111/all.13972 · Cited by 34
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma
Prabhu, S. A., Moussa, O., Miller, W. H., & Rincon, S. V. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114055 · Cited by 36
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
Rizzo, A., Federico, A. D., Ricci, A. D., Frega, G., Palloni, A., Pagani, R., Tavolari, S., Marco, M. D., & Brandi, G. (2020) · Cancer Control · doi:10.1177/1073274820983013 · Cited by 34
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells
Atay, Ç., Kwak, T., Lavilla-Alonso, S., Donthireddy, L., Richards, A. D., Moberg, V. E., Pilon‐Thomas, S., Schell, M. J., Messina, J. L., Rebecca, V. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2725 · Cited by 34
Self-citationAntonello, Z. A., & Nucera, C. (2013) · Oncogene · doi:10.1038/onc.2013.544 · Cited by 33
The evolving field of kinase inhibitors in thyroid cancer
Marotta, V., Sciammarella, C., Vitale, M., Colao, A., & Faggiano, A. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.08.007 · Cited by 33
Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK
Vin, H., Ching, G., Ojeda, S. S., Adelmann, C. H., Chitsazzadeh, V., Dwyer, D. W., Ma, H., Ehrenreiter, K., Baccarini, M., Ruggieri, R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0561 · Cited by 36
Sullivan, R. J., Lawrence, D. P., Wargo, J. A., Oh, K. S., Gonzalez, R. G., & Piris, A. (2013) · New England Journal of Medicine · doi:10.1056/nejmcpc1302332 · Cited by 34
Self-citationVouk, K., Benter, U., Amonkar, M. M., Marocco, A., Stapelkamp, C., Pfersch, S., & Benjamin, L. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1184155 · Cited by 33
Rao, S. N., & Cabanillas, M. E. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00180 · Cited by 33
Shadbad, M. A., Hajiasgharzadeh, K., Derakhshani, A., Silvestris, N., Baghbanzadeh, A., Racanelli, V., & Baradaran, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623639 · Cited by 33
Autophagy Inhibition in BRAF-Driven Cancers
Foth, M., & McMahon, M. (2021) · Cancers · doi:10.3390/cancers13143498 · Cited by 33
Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue
Loria, R., Vici, P., Lisa, F. S. D., Soddu, S., Maugeri‐Saccà, M., & Bon, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877380 · Cited by 34
Algazi, A. P., Cha, E., Ortiz‐Urda, S., McCalmont, T. H., Bastian, B. C., Hwang, J. H., Pampaloni, M. H., Behr, S. C., Chong, K., Cortez, B., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.541 · Cited by 33
Lai, F., Jiang, C. C., Farrelly, M. L., Zhang, X. D., & Hersey, P. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328353eff2 · Cited by 33
Self-citationAdapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma
Demirsoy, Ş., Martín-Acebes, M. A., Maes, H., & Agostinis, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00240 · Cited by 35
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome
Perico, L., Mandalà, M., Schieppati, A., Carrara, C., Rizzo, P., Conti, S., Longaretti, L., Benigni, A., & Remuzzi, G. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.013 · Cited by 33
Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma
Hoffman, R. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091875 · Cited by 33
Metadata
- Authors
- Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K. D., Amaravadi, R. K., Chmielowski, B., Lawrence, H. J., Shyr, Y., Ye, F., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K., & Ribas, A.
- Affiliations
- Vanderbilt University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Abramson Cancer Center (US)
- University of Colorado Denver (US)
- New York University (US)
- Moffitt Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- University of Newcastle Australia (AU)
- Melanoma Institute Australia (AU)
- Vanderbilt-Ingram Cancer Center (US)
- University of California, Los Angeles (US)
- Vanderbilt University Medical Center (US)
- Plexxikon (United States) (US)
- ORCID
- Sosman, Jeffrey A.
- Kim, Kevin B.
- Schuchter, Lynn
- Gonzalez, Rene
- Pavlick, Anna C.
- Weber, Jeffrey S.
- McArthur, Grant A.
- Hutson, Thomas E.
- Moschos, Stergios J.
- Flaherty, Keith T.
- Hersey, Peter
- Kefford, Richard
- Lawrence, Donald
- Puzanov, Igor
- Lewis, Karl D.
- Amaravadi, Ravi K.
- Chmielowski, Bartosz
- Shyr, Yu
- Ye, Fei
- Li, Jiang
- Lee, Richard J.
- Ribas, Antoni
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-23
- Volume
- 366
- Issue
- 8
- Pages
- 707-714
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3724515
- OpenAlex
- W2168143310
- Cited by
- 2,156
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 56 · 2023: 85 · 2022: 113 · 2021: 88 · 2020: 110 · 2019: 109 · 2018: 132 · 2017: 171 · 2016: 198 · 2015: 258 · 2014: 318 · 2013: 306 · 2012: 160
- FWCI
- 133.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (K24CA097588, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, metastatic melanoma, BRAF inhibitors, overall survival, overall response rate, duration of response, progression-free survival, cutaneous squamous cell carcinoma, keratoacanthoma, adverse events
- MeSH terms
- Vemurafenib, Adult, Aged, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Sulfonamides, Treatment Outcome, Disease Progression, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
